Q1 2025 Management View CEO Pascal Soriot emphasized that AstraZeneca's total revenue grew by 10% in Q1 2025, with core operating profit increasing by 12% and core EPS by 21%. Growth was supported by ...

In recent years, inhibiting PCSK9, a serine proteinase that regulates cholesterol metabolism, has been demonstrated to be a method enhancing the antitumor effects of anti-PD-1/PD-L1 treatment to ...

A new study conducted at Cedars-Sinai reveals how the cholesterol-reducing drug evolocumab prevents heart attacks in people ...

"We've had PCSK9 inhibitors on the market in the United States for 10 years," said investigator Michael Koren, MD, a cardiologist and CEO of the ENCORE Research Group in Jacksonville, Florida.

A once-daily oral PCSK9 inhibitor reduced LDL in patients with hypercholesterolemia. Safety and tolerability profiles were favorable, according to investigators. CHICAGO — In a phase 2b study ...

Verve Therapeutics has generated evidence its PCSK9 pivot could pay off. One year after dropping a base editing candidate over a safety signal, the biotech has shown its Eli Lilly-partnered ...

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a protein that binds to the LDL receptor on hepatocytes, promoting its internalization and degradation within the cell. [Repatha package ...

A new study by Cardia Vision, LLC has revealed that a commonly used heart scan may be missing signs of early heart disease in ...

Single infusion of VERVE-102 led to dose-dependent decreases in blood PCSK9 and LDL-C, with mean reduction in LDL-C of 53% and a maximum reduction of 69% observed in the 0.6 mg/kg dose cohort ...